HC Wainwright & Co. Initiates Coverage On Ultragenyx Pharmaceutical with Buy Rating, Announces Price Target of $106
HC Wainwright & Co. analyst Edwin Zhang initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy rating and announces Price Target of $106.
Ultragenyx Reports Crysvita, UX143 Data Presentations At Upcoming American Society For bone, Mineral Research 2021 Annual Meeting Oct. 1-4
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that new
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc’s (NASDAQ:RARE) GTX-102 trial for Angelman syndrome. The companies can…
Ultragenyx Pharma Reports Approval Of Dojolvi In Brazil For Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Adults, Children
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Brazil’s National Health
Return on Capital Employed Insights for Ultragenyx Pharmaceutical
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx Pharmaceutical still reported an overall loss of $82.78 million.
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Sell Rating, Announces Price Target of $73
UBS analyst Esther Rajavelu initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Sell rating and announces Price Target of $73.
Return on Capital Employed Overview: Ultragenyx Pharmaceutical
After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx Pharmaceutical still reported an overall loss of $82.78 million.
Ultragenyx Pharmaceutical Q2 EPS $(1.81) Misses $(1.36) Estimate, Sales $86.97M Beat $85.03M Estimate
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.36) by 33.09 percent. This is a 61.61 percent decrease over losses of $(1.12) per